Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy. [electronic resource]
Producer: 20141010Description: 35-40 p. digitalISSN:- 2291-2797
- Adolescent
- Adult
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Antiviral Agents -- therapeutic use
- Biomarkers -- blood
- Canada
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- genetics
- Hepatitis C -- blood
- Humans
- Infliximab
- Interferon alpha-2
- Interferon-alpha -- therapeutic use
- Male
- Middle Aged
- Pilot Projects
- Polyethylene Glycols -- therapeutic use
- Prospective Studies
- Recombinant Proteins -- therapeutic use
- Ribavirin -- therapeutic use
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- blood
- Viral Load -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.